独家报道：一个由两党议员组成、成员超过50人的团体正敦促特朗普政府不要敲定一项与拜登任内药品价格谈判计划有关的拟议医保政策，认为该政策可能打击研发改良型癌症治疗的积极性。福克斯新闻数字网9月21日获得的一封信显示，这些议员敦促美国医疗保险与医疗补助服务中心（CMS）管理员穆罕默德·奥兹博士，将该机构拟议的固定剂量复方制剂政策从实施医保药品价格谈判计划的最终规则中删除。
EXCLUSIVE: A bipartisan group of more than 50 lawmakers is urging the Trump administration not to finalize a proposed Medicare policy tied to the Biden-era drug price negotiation program, arguing it could discourage development of improved cancer treatments. In a Sept. 21 letter obtained by Fox News Digital, the lawmakers called on Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz to remove the agency's proposed fixed-dose combination policy from its final rule implementing Medicare's Drug Price Negotiation Program.
医保药品价格谈判计划依据《通胀削减法案》设立，前总统乔·拜登于2022年签署该法案，使其成为法律。特朗普政府于6月提出这项政策，作为实施该计划的一部分。争议的核心在于，医保在价格谈判中应如何处理现有药物的较新版本。奥兹博士警告：医保骗子正窃取数十亿美元——你的个人信息也可能成为目标。这些议员认为，该提案将导致某些改良疗法在获得美国食品药品监督管理局（FDA）批准后，很快便须接受医保价格谈判，而不必等待很长时间。
The Medicare Drug Price Negotiation Program was created under the Inflation Reduction Act, which former President Joe Biden signed into law in 2022. The Trump administration proposed the policy in June as part of implementing that program. At the center of the dispute is how Medicare would treat newer versions of existing drugs for price negotiation purposes. DR OZ WARNS MEDICARE SCAMMERS ARE STEALING BILLIONS — AND YOUR PERSONAL INFORMATION COULD BE NEXT The lawmakers argue the proposal would cause some improved treatments to face Medicare price negotiations much sooner after receiving Food and Drug Administration (FDA) approval.
他们表示，这将削弱药品制造商研发现有药物更优版本的动力。“如果最终敲定，拟议的固定剂量复方制剂政策将使这些研发成果在获FDA批准后几乎立即被纳入价格谈判，损害患者获得这些改良疗法的机会，也削弱研发这些改良疗法的动力。”这些议员写道。与此同时，美国医疗保险与医疗补助服务中心表示，该提案旨在防止药品制造商通过对现有药物仅作有限改动、再将其作为新产品推出，来规避或推迟适用医保谈判价格。
They say that would reduce incentives for drugmakers to develop better versions of existing medicines. "If finalized, the proposed fixed-dose combination policy would subject these advancements to negotiation almost immediately after FDA approval, harming patient access as well as incentives to develop these improved therapies," the lawmakers wrote. CMS, meanwhile, said the proposal is designed to prevent drugmakers from avoiding or delaying negotiated Medicare prices by making only limited changes to existing drugs and introducing them as new products.
奥兹博士将5个州列为欺诈行为的重点打击对象；特朗普政府同时也在打击医疗补助（Medicaid）领域的滥用行为。
DR OZ NAMES 5 STATES IN FRAUD CRACKDOWN AS TRUMP ADMINISTRATION TARGETS MEDICAID ABUSE The lawmakers pointed to advances in cancer immunotherapy that allow some patients to receive a quick injection instead of spending hours receiving an intravenous infusion.
这些议员指出，癌症免疫疗法取得了重大进展——部分患者现在只需接受一次注射治疗，而无需花费数小时进行静脉输液。他们认为这些新疗法能够使治疗过程更快、更便捷，尤其是对农村地区的患者而言。信中写道：“与癌症抗争的患者理应获得最先进的新疗法；如果医疗保险管理局（CMS）最终通过这项提案，这些先进疗法很可能无法惠及最需要它们的人。”
They said those improvements can make treatment faster, easier and more accessible, particularly for patients in rural areas. "Patients fighting cancer deserve access to the most advanced new therapies, and if CMS finalizes this proposal, those advances are less likely to reach those who need it the most," the letter states.
议员们还指出，美国食品药品监督管理局（FDA）早已将这些疗法视为独立的药物进行评估，因此需要分别进行临床试验和审批程序。他们建议CMS应将这些疗法作为独立的药物纳入医疗保险药品价格谈判计划中。此外，议员们认为CMS的精算师们“未能证明这项政策能为纳税人带来实质性的节省”。
The lawmakers also argued the FDA already evaluates the therapies as separate medicines, requiring separate clinical trials and approvals. They said CMS should treat those therapies as separate medicines under the Medicare drug price negotiation program.
信中还提到了一种有助于改善退休人员健康状况的饮食习惯，该习惯可能为美国带来1万亿美元的额外收入。信中强烈呼吁CMS撤回有关“固定剂量组合药物”的提案，并强调：“我们代表的患者需要那些能够扩大救命医疗资源获取范围、并鼓励医学进步与创新的政策。”
The lawmakers also argued that CMS actuaries "have not been able to show this policy would produce meaningful savings for taxpayers." DR OZ REVEALS THE HEALTHY RETIREMENT HABIT THAT COULD MAKE AMERICA $1 TRILLION RICHER "We strongly urge CMS to withdraw the fixed-dose combination proposal from the final rule," the letter states.
参与起草这封信的议员来自两党，包括来自宾夕法尼亚州的约翰·乔伊斯（John Joyce）、伊利诺伊州的达林·拉胡德（Darin LaHood）、犹他州的迈克·肯尼迪（Mike Kennedy）、北卡罗来纳州的蒂姆·摩尔（Tim Moore）以及加利福尼亚州的吉姆·科斯塔（Jim Costa）等。
"The patients we represent need policies that expand access to lifesaving care and reward medical progress and innovation in the treatment of deadly diseases." awmakers from both parties, including Reps. John Joyce, R-Pa., Darin LaHood, R-Ill., Mike Kennedy, R-Utah, Tim Moore, R-N.C., Jim Costa, D-Calif., Donald Davis, D-N.C., and more.
福克斯新闻数字频道（Fox News Digital）未能立即联系到CMS部门获取评论。
CMS could not immediately be reached by Fox News Digital for comment.